← Eichor
Condition: Idh1 Mutant Glioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Idh1 Mutant Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3 · 57 location(s) · Nuvation Bio Inc. · NCT05303519ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
Phase 1 · 1 location(s) · Katy Peters, MD, PhD · NCT05609994Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
Phase N/A · 1 location(s) · Xiangya Hospital of Central South University · NCT07608003
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.